ANA Test Results Interpretation Guide

Published

Last updated

Key takeaway:

ANA results combine a titer — the dilution ratio at which antibodies are still detectable — with a staining pattern that points to specific autoimmune conditions. Around 13–14% of healthy U.S. adults test positive at the 1:80 cutoff with no disease; titers of 1:160 or higher paired with symptoms require closer clinical evaluation.

Read more →

Understand what your general health testing results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

A negative ANA makes autoimmune disease unlikely. About 13-14% of healthy U.S. adults test positive at 1:80. A titer of 1:160 or higher with symptoms warrants follow-up.

How titer and staining pattern work

Your ANA test measures two critical components: titer levels and staining patterns. Think of titer as the dilution strength where your antibodies still show up. A 1:80 titer means your blood was diluted 80 times and still tested positive. A 1:160 titer required 160-fold dilution to detect antibodies.

TiterWhat it means
1:40Below most labs' positive cutoff; common in healthy adults and usually background noise
1:80Positive at most labs, though the cutoff varies; found in about 13-14% of healthy U.S. adults with no autoimmune disease
1:160Yes, positive, and worth closer attention; may reflect autoimmune activity, especially with symptoms, but does not confirm active disease
1:320 or higherSame follow-up as 1:160, weighed with symptoms and pattern; most people with lupus test at 1:160 or higher

The staining pattern reveals which part of the cell nucleus your antibodies target.

PatternWhat it looks likeAssociated conditions
HomogeneousSmooth, even stainingLupus or drug-induced autoimmunity; with joint pain and fatigue, may prompt lupus evaluation
Coarse speckledLarger, chunky dotsSjögren's syndrome, mixed connective tissue disease, or scleroderma; with dry eyes and mouth, could indicate Sjögren's syndrome
Dense fine speckled (DFS70)Smaller, finer dotsOften seen in healthy people; generally not tied to autoimmune disease
NucleolarConcentrated dotsScleroderma; with skin tightening, warrants scleroderma assessment
CentromereDistinct paired dotsLimited cutaneous systemic sclerosis

The combination of titer strength and specific pattern provides much more information than either measurement alone.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

What a positive ANA HEp-2 result means

A positive ANA HEp-2 result means antinuclear antibodies were detected by indirect immunofluorescence (IFA) on HEp-2 cells, the widely used ANA screening method. A positive result does not confirm disease on its own. Your titer, staining pattern, and symptoms decide what it means.

Your healthcare provider will also factor in your age, sex, and family history. Women develop positive ANA results more frequently than men. Having relatives with autoimmune conditions increases your likelihood of developing them too.

Remember that positive ANA results can appear months or years before symptoms develop. This makes regular monitoring valuable, even when you feel perfectly healthy. All ANA results should be interpreted by healthcare professionals who can consider your complete clinical picture.

What can influence ANA test results

Several factors can create false positives or affect result interpretation. Age significantly impacts ANA prevalence. ANA prevalence rises meaningfully with age, from lower rates in young adults to roughly 15-25% in adults over 50-65, depending on titer cutoff and population studied. This age-related increase often reflects accumulated immune system changes rather than disease.

Medications can trigger positive results. Hydralazine, procainamide, and some anti-seizure drugs commonly are associated with drug-induced lupus with positive ANA. Birth control pills, antibiotics, and heart medications occasionally elevate ANA levels too.

Infections temporarily boost autoantibody production. Viral infections like Epstein-Barr virus, cytomegalovirus, or COVID-19 can create transient positive results. Bacterial infections and parasitic diseases sometimes trigger ANA production as well.

Laboratory variations affect results consistency. Different labs use different cell types, dilution protocols, and interpretation criteria. Always retest concerning results at the same laboratory when possible. Stress, pregnancy, and recent vaccinations can also influence antibody levels.

Test 100+ biomarkers

One blood draw. A full picture of your health, explained in plain language.

Book your test

Follow-up antibody tests after a positive ANA

ANA results gain meaning when viewed alongside specific autoantibody tests. Anti-dsDNA antibodies with positive ANA may suggest lupus, especially with kidney involvement. Anti-SSA/SSB antibodies may indicate Sjögren's syndrome risk. Anti-Scl-70 antibodies may point toward diffuse scleroderma. Anti-centromere antibodies are associated with limited scleroderma.

Complement levels (C3 and C4) provide additional context. Low complement with positive ANA often indicates active autoimmune inflammation. Normal complement levels suggest less active disease, even with positive antibodies.

Inflammatory markers like ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) help distinguish between active autoimmune disease and benign positive results. Elevated inflammatory markers with positive ANA warrant more aggressive evaluation. CRP is often normal in uncomplicated lupus flares, so a markedly elevated CRP in someone with known SLE may point to infection or serositis rather than a classic lupus flare.

Your complete blood count can reveal autoimmune complications. Low white blood cell counts, anemia, or reduced platelets combined with positive ANA might indicate systemic lupus erythematosus. These patterns help your healthcare provider prioritize follow-up testing and monitoring strategies.

Take control of your autoimmune health

Tracking ANA over time, alongside immune and inflammatory markers, shows whether your results are stable or changing. Superpower's biomarker testing includes immune system markers, inflammatory indicators, and complement levels that add context to ANA results. Review them with your healthcare provider.

Frequently Asked Questions

References

  1. Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, Garcia de la Torre I, Herold M, Klotz W, Cruvinel WM, Mimori T, von Muhlen C, Satoh M, Chan EK (2019). Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. *Annals of the rheumatic diseases*, *78*(7), 879-889. https://doi.org/10.1136/annrheumdis-2018-214436
  2. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE (2011). Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. *Arthritis and rheumatism*, *63*(1), 191-200. https://doi.org/10.1002/art.30084
  3. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, ... Pope JE (2013). 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. *Annals of the rheumatic diseases*, *72*(11), 1747-55. https://doi.org/10.1136/annrheumdis-2013-204424
  4. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, ... Johnson SR (2019). 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis & rheumatology (Hoboken, N.J.)*, *71*(9), 1400-1412. https://doi.org/10.1002/art.40930
  5. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, Jusko TA, Walker NJ, Germolec DR, Whitt IZ, Crockett PW, Pauley BA, Chan JY, Ross SJ, Birnbaum LS, Zeldin DC, Miller FW (2012). Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. *Arthritis and rheumatism*, *64*(7), 2319-27. https://doi.org/10.1002/art.34380
  6. Selmi C, Ceribelli A, Generali E, Scirè CA, Alborghetti F, Colloredo G, Porrati L, Achenza MI, De Santis M, Cavaciocchi F, Massarotti M, Isailovic N, Paleari V, Invernizzi P, Matthias T, Zucchi A, Meroni PL (2016). Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. *Autoimmunity reviews*, *15*(2), 162-6. https://doi.org/10.1016/j.autrev.2015.10.007
  7. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X, International Sjögren's Syndrome Criteria Working Group (2017). 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis & rheumatology (Hoboken, N.J.)*, *69*(1), 35-45. https://doi.org/10.1002/art.39859
  8. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003). Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *The New England journal of medicine*, *349*(16), 1526-33. https://doi.org/10.1056/NEJMoa021933
  9. Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM, Moroni G (2018). Drug-induced lupus: Traditional and new concepts. *Autoimmunity reviews*, *17*(9), 912-918. https://doi.org/10.1016/j.autrev.2018.03.016
  10. Ding BN, Wu YL, Zhang YY, Li YG (2024). Association between Epstein-Barr virus infection and serum positivity rate of anti-nuclear antibodies in Chongqing, China: A cross-sectional observational study. *Medicine*, *103*(32), e39233. https://doi.org/10.1097/MD.0000000000039233
  11. Hromić-Jahjefendić A, Lundstrom K, Adilović M, Aljabali AAA, Tambuwala MM, Serrano-Aroca, Á., Uversky VN (2024). Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines. *Autoimmunity reviews*, *23*(3), 103508. https://doi.org/10.1016/j.autrev.2023.103508

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Biological age 32 — a Superpower member portraitA health system built around you — test, understand, optimize100+ biomarkers across 2 blood drawsWhat to expect with Superpower — week 1 to month 3Trusted by 64,000+ customers — member reviewsBetter than the status quo — Superpower vs the old way60% of members found something a doctor missed — member survey
Daniel OSuperpower memberDavid LSuperpower memberRachel DSuperpower memberCamelia VSuperpower member

4.6 · 64,000+ members

Superpower health membership

Find early signs of 1,000+ conditions from a single blood draw - then act on what you find.

$199

/year*

100+ biomarkers from a single blood draw

Personalized plan that turns results into action

Superpower AI and on-demand care team

Results in 10 days or less

At-home or 2,000+ labs nationwide**

Yearly membership$0.55 / dayHSA/FSA eligible

*Pricing may vary for members in New York and New Jersey

**At-home labs for an additional cost

What we test

TestosteroneFree T4Vitamin DApoBHbA1cThyroid (TSH)hs-CRPFerritinCortisolFasting insulin

60%

found something a doctor missed

93%

rated it more useful than their checkup

77%

found something new in their results

Superpower member survey, 90 days post action plan (n=143).

How does the Superpower membership work?

We test 100+ biomarkers from a single blood draw each year. Your baseline test paints a comprehensive picture of your health, and your dashboard shows what’s working, what needs attention, and what to do next. Superpower AI and your care team help you take action across lifestyle, supplements, and treatments.

Can I cancel anytime?

Yes. You can cancel anytime, no fees. Your membership stays active through the end of your paid year.

How often should I test?

Your membership includes two blood tests per year: one to establish your baseline, and one to see whether your plan improved biomarkers that were out of range or not yet optimized. You can add other diagnostics anytime through the app or with help from your care team.

When will I get my results?

Book your draw at any of 2,000+ partner labs or at-home. Results are typically ready in about a week and land in the Superpower app.